For research use only.
PeptaBase is for informational and laboratory research reference only.
No medical claims are made and nothing on this site is intended to diagnose, treat, cure or prevent any disease.
Follistatin-344 Protocol
Dosing & Research
Last Updated: September 4, 2026
Also known as: FS-344, Follistatin 344, FST-344, Follistatin-344
Myostatin inhibition, Muscle growth research, Sarcopenia and muscle wasting models, Skeletal muscle mass studies
Half-Life
Not Well Characterized In Humans
Administration
Subcutaneous
Frequency
Daily or every other day for 10-30 days; or 2x weekly for 8-12 weeks
How It Works
- Myostatin inhibition
- Muscle growth research
- Sarcopenia and muscle wasting models
- Skeletal muscle mass studies
Dosing Structure
Dose
100–200 mcg per injection
Frequency
Daily or every other day for 10-30 days; or 2x weekly for 8-12 weeks
Notes
Loading Phase: 100–200 mcg daily for 10–30 days. Some protocols: daily for 7 days, then 2x weekly maintenance for 8–12 weeks. Cycle: 3–4 weeks off between cycles. Inject: Abdomen, thigh (rotate). Note: No human clinical trials for subcutaneous form; dosing based on animal studies and community protocols. Strong evidence from AAV gene therapy studies showing 20%+ muscle mass increases in animal models.
Example Protocols
Dose: 100–200 mcg per injection
Frequency: Daily or every other day for 10-30 days; or 2x weekly for 8-12 weeks
Duration: 10–30 days or 8–12 weeks; 3–4 weeks break
Off Period: Not listed
Find Research Grade Follistatin-344
Recommended vendors for sourcing research-grade material. PeptaBase does not sell peptides directly.
Vendor One Research Labs
COA VerifiedThird-party COA-verified research peptides with published batch testing.
Source Coming SoonVendor Two Sciences
Purity TestedUS-based research compound supplier with independent purity testing.
Source Coming SoonVendor Three Peptide Co.
Bulk research peptide sourcing with batch-level documentation.
Source Coming SoonProtocol Notes
•Loading Phase: 100–200 mcg daily for 10–30 days.
•Some protocols: daily for 7 days, then 2x weekly maintenance for 8–12 weeks.
•Cycle: 3–4 weeks off between cycles.
•Inject: Abdomen, thigh (rotate).
•Note: No human clinical trials for subcutaneous form; dosing based on animal studies and community protocols.
•Strong evidence from AAV gene therapy studies showing 20%+ muscle mass increases in animal models.
Research & Studies
Loading citations…
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Be the first to submit research feedback for this peptide.
Approved submissions will appear here as aggregated insights.